BioSpace News Archive

In honor of World Kidney Day on Thursday, March 11, the National Kidney Foundation’s national public awareness campaign, “Are You the 33%?”, asks all Americans to take action with a simple, one-minute quiz at MinuteForYourKidneys.org to find out if they’re at risk for kidney disease.

Dermavant Sciences announced that an abstract containing interim analysis data from Dermavant’s PSOARING 3 long-term, open-label safety study for tapinarof for the treatment of psoriasis in adults will be presented in poster format during the upcoming Innovations in Dermatology Virtual Spring Conference 2021, held from March 16-20, 2021.

Tvardi Therapeutics (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Michael Wyzga, former Chief Financial Officer of Genzyme, to its Board of Directors.

Focus on achieving better precision in cancer diagnosis and treatment, targeting only affected cells will fuel demand for cancer RNA expressions

Increasing dog ownership across key geographies is prompting greater canine healthcare infrastructure deployment

Aprotinin, or bovine pancreatic trypsin inhibitor (BPTI), is a protein-based drug. Aprotinin has the capacity to slow fibrinolysis; hence, it has been utilized to minimize bleeding during complicated surgical procedures including heart and liver surgeries.

Cat-scratch disease (CSD) is an infection caused by cats. The disease transmits when an infected cat licks an open wound on a human or either scratches the person hard enough to break the surface of the skin.

Surgical cannulae is one of the most commonly used devices in surgical procedures and operations.

The demand within the global DNA/gene microarray market is expected to rise alongside advancements in genetic studies.

The REMDACTA clinical trial of Actemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone